FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016804329> ?p ?o ?g. }

• W2016804329 endingPage "812" @default.
• W2016804329 startingPage "809" @default.
• W2016804329 abstract "Leukaemia relapse remains a major cause of treatment failure after allogeneic haemopoietic-cell transplantation for patients with advanced-phase chronic myelogenous leukaemia or Philadelphia-chromosome-positive acute lymphoblastic leukaemia. By contrast with cytogenetic or haematological relapse, patients who relapse with blast-phase chronic myelogenous leukaemia or Philadelphia-chromosome-positive acute lymphoblastic leukaemia have a low probability of responding to donor-lymphocyte infusions 1 Collins Jr, RH Shpilberg O Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone-marrow transplantation. J Clin Oncol. 1997; 15: 433-444 Crossref PubMed Scopus (1114) Google Scholar , 2 Alyea EP Soiffer RJ Canning C et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998; 91: 3671-3680 Crossref PubMed Google Scholar or imatinib when given alone. 3 Olavarria E Ottmann OG Deininger M et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 2003; 17: 1707-1712 Crossref PubMed Scopus (101) Google Scholar , 4 Shimoni A Kroger N Zander AR et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia. 2003; 17: 290-297 Crossref PubMed Scopus (79) Google Scholar Here, we report a favourable outcome in two patients treated at our institution who were given imatinib combined with donor-lymphocyte infusions as salvage treatment for relapse in advanced-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative allogeneic haemopoietic-cell transplantation." @default.
• W2016804329 created "2016-06-24" @default.
• W2016804329 creator A5007244861 @default.
• W2016804329 creator A5012686649 @default.
• W2016804329 creator A5014445762 @default.
• W2016804329 creator A5031748968 @default.
• W2016804329 creator A5048398919 @default.
• W2016804329 creator A5049066393 @default.
• W2016804329 creator A5063057686 @default.
• W2016804329 creator A5076074380 @default.
• W2016804329 creator A5087735516 @default.
• W2016804329 creator A5088962035 @default.
• W2016804329 date "2005-10-01" @default.
• W2016804329 modified "2023-09-27" @default.
• W2016804329 title "Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib" @default.
• W2016804329 cites W1707184873 @default.
• W2016804329 cites W175951554 @default.
• W2016804329 cites W1873141201 @default.
• W2016804329 cites W2070382898 @default.
• W2016804329 cites W2083971244 @default.
• W2016804329 cites W2084948372 @default.
• W2016804329 cites W2118032143 @default.
• W2016804329 cites W2142900411 @default.
• W2016804329 cites W2169534778 @default.
• W2016804329 cites W2320970881 @default.
• W2016804329 doi "https://doi.org/10.1016/s1470-2045(05)70391-0" @default.
• W2016804329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16198987" @default.
• W2016804329 hasPublicationYear "2005" @default.
• W2016804329 type Work @default.
• W2016804329 sameAs 2016804329 @default.
• W2016804329 citedByCount "15" @default.
• W2016804329 countsByYear W20168043292012 @default.
• W2016804329 countsByYear W20168043292013 @default.
• W2016804329 countsByYear W20168043292014 @default.
• W2016804329 countsByYear W20168043292018 @default.
• W2016804329 countsByYear W20168043292020 @default.
• W2016804329 crossrefType "journal-article" @default.
• W2016804329 hasAuthorship W2016804329A5007244861 @default.
• W2016804329 hasAuthorship W2016804329A5012686649 @default.
• W2016804329 hasAuthorship W2016804329A5014445762 @default.
• W2016804329 hasAuthorship W2016804329A5031748968 @default.
• W2016804329 hasAuthorship W2016804329A5048398919 @default.
• W2016804329 hasAuthorship W2016804329A5049066393 @default.
• W2016804329 hasAuthorship W2016804329A5063057686 @default.
• W2016804329 hasAuthorship W2016804329A5076074380 @default.
• W2016804329 hasAuthorship W2016804329A5087735516 @default.
• W2016804329 hasAuthorship W2016804329A5088962035 @default.
• W2016804329 hasConcept C104317684 @default.
• W2016804329 hasConcept C126322002 @default.
• W2016804329 hasConcept C138626823 @default.
• W2016804329 hasConcept C143998085 @default.
• W2016804329 hasConcept C185592680 @default.
• W2016804329 hasConcept C2776960273 @default.
• W2016804329 hasConcept C2777408962 @default.
• W2016804329 hasConcept C2777583451 @default.
• W2016804329 hasConcept C2778461978 @default.
• W2016804329 hasConcept C2778729363 @default.
• W2016804329 hasConcept C2778904597 @default.
• W2016804329 hasConcept C2779695342 @default.
• W2016804329 hasConcept C28328180 @default.
• W2016804329 hasConcept C2911091166 @default.
• W2016804329 hasConcept C3019892230 @default.
• W2016804329 hasConcept C54355233 @default.
• W2016804329 hasConcept C55493867 @default.
• W2016804329 hasConcept C71924100 @default.
• W2016804329 hasConcept C86803240 @default.
• W2016804329 hasConceptScore W2016804329C104317684 @default.
• W2016804329 hasConceptScore W2016804329C126322002 @default.
• W2016804329 hasConceptScore W2016804329C138626823 @default.
• W2016804329 hasConceptScore W2016804329C143998085 @default.
• W2016804329 hasConceptScore W2016804329C185592680 @default.
• W2016804329 hasConceptScore W2016804329C2776960273 @default.
• W2016804329 hasConceptScore W2016804329C2777408962 @default.
• W2016804329 hasConceptScore W2016804329C2777583451 @default.
• W2016804329 hasConceptScore W2016804329C2778461978 @default.
• W2016804329 hasConceptScore W2016804329C2778729363 @default.
• W2016804329 hasConceptScore W2016804329C2778904597 @default.
• W2016804329 hasConceptScore W2016804329C2779695342 @default.
• W2016804329 hasConceptScore W2016804329C28328180 @default.
• W2016804329 hasConceptScore W2016804329C2911091166 @default.
• W2016804329 hasConceptScore W2016804329C3019892230 @default.
• W2016804329 hasConceptScore W2016804329C54355233 @default.
• W2016804329 hasConceptScore W2016804329C55493867 @default.
• W2016804329 hasConceptScore W2016804329C71924100 @default.
• W2016804329 hasConceptScore W2016804329C86803240 @default.
• W2016804329 hasIssue "10" @default.
• W2016804329 hasLocation W20168043291 @default.
• W2016804329 hasLocation W20168043292 @default.
• W2016804329 hasOpenAccess W2016804329 @default.
• W2016804329 hasPrimaryLocation W20168043291 @default.
• W2016804329 hasRelatedWork W1966049407 @default.
• W2016804329 hasRelatedWork W2011474502 @default.
• W2016804329 hasRelatedWork W2053904016 @default.
• W2016804329 hasRelatedWork W2081284522 @default.
• W2016804329 hasRelatedWork W2091513953 @default.
• W2016804329 hasRelatedWork W2096135025 @default.
• W2016804329 hasRelatedWork W2149056079 @default.
• W2016804329 hasRelatedWork W2161371522 @default.

• next